Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01556282 · ClinicalTrials.gov registry record · NA
TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis
A NA study, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 35
- Enrollment target
NCT01556282 is a NA study that has completed, run by Emory University. The registered enrollment target is 35 participants.
The verdict
NCT01556282, a NA study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
Study Summary
Therasphere will be administered via catheter through the Hepatic Artery to treat patients with Hepatocellular Carcinoma and Portal vein Thrombosis.
Interventions
- DEVICE TheraSphere
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2009-03 |
| Est. Completion | 2014-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01556282
The ClinicalTrials.gov registry entry for NCT01556282 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TheraSphere is the first listed.
NCT01556282 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01556282 about?
NCT01556282 is a clinical study titled "TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis". Therasphere will be administered via catheter through the Hepatic Artery to treat patients with Hepatocellular Carcinoma and Portal vein Thrombosis.
What is the current status of trial NCT01556282?
This trial is currently completed. It is a NA study. The enrollment target is 35 participants. The study started on 2009-03. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01556282?
The interventions under investigation include: TheraSphere (DEVICE).
Who is sponsoring clinical trial NCT01556282?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.